The Israeli institute will share its expertise on translating research into commercially viable applications with the goal of advancing personalized medicine.
Researchers are developing a nanopore sensing device that relies on restriction enzymes to target specific clinically relevant variants in pathogens.
Technion's Reut Shalgi is building up her lab to study how chaperones affect protein synthesis and protein folding.
The majority of the funding will be used to establish a cancer metabolomics research center on Technion's campus.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.